Ubs Group Ag Amylyx Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 229,076 shares of AMLX stock, worth $1.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

229,076

Previous 30,139 660.07%

Holding current value

$1.21 Million

Previous $57,000 1201.75%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.65 - $3.24 $328,246 - $644,555	198,937 Added 660.07%	229,076 $742,000
Q2 2024 Aug 13, 2024	SELL	$1.62 - $2.71 $292,303 - $488,976	-180,434 Reduced 85.69%	30,139 $57,000
Q1 2024 May 13, 2024	BUY	$2.71 - $19.57 $464,924 - $3.36 Million	171,559 Added 439.74%	210,573 $598,000
Q4 2023 Feb 09, 2024	BUY	$12.07 - $18.46 $415,244 - $635,079	34,403 Added 746.11%	39,014 $574,000
Q3 2023 Nov 09, 2023	SELL	$18.08 - $23.45 $1.26 Million - $1.63 Million	-69,464 Reduced 93.78%	4,611 $84,000
Q2 2023 Aug 11, 2023	BUY	$20.98 - $31.42 $577,411 - $864,741	27,522 Added 59.12%	74,075 $1.6 Million
Q1 2023 May 12, 2023	BUY	$27.71 - $40.93 $1.19 Million - $1.76 Million	43,076 Added 1238.88%	46,553 $1.37 Million
Q4 2022 Feb 08, 2023	SELL	$29.75 - $39.26 $15,172 - $20,022	-510 Reduced 12.79%	3,477 $128,000
Q3 2022 Nov 10, 2022	BUY	$17.15 - $30.92 $65,341 - $117,805	3,810 Added 2152.54%	3,987 $112,000
Q2 2022 Aug 10, 2022	SELL	$6.85 - $19.93 $27,263 - $79,321	-3,980 Reduced 95.74%	177 $3,000
Q1 2022 May 16, 2022	BUY	$12.85 - $32.9 $53,417 - $136,765	4,157 New	4,157 $53,000

Others Institutions Holding AMLX

# of Institutions

127

Shares Held

44.4M

Call Options Held

235K

Put Options Held

530K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account